| Literature DB >> 21666796 |
Joachim Blocher1, Erich Schmutzhard, Patricia P Wilkins, Paige N Gupton, Matthias Schaffert, Herbert Auer, Thaddaeus Gotwald, William Matuja, Andrea S Winkler.
Abstract
Neurocysticercosis (NCC) is a major cause of epilepsy in regions where pigs are free-ranging and hygiene is poor. Pork production is expected to increase in the next decade in sub-Saharan Africa, hence NCC will likely become more prevalent. In this study, people with epilepsy (PWE, n=212) were followed up 28.6 months after diagnosis of epilepsy. CT scans were performed, and serum and cerebrospinal fluid (CSF) of selected PWE were analysed. We compared the demographic data, clinical characteristics, and associated risk factors of PWE with and without NCC. PWE with NCC (n=35) were more likely to be older at first seizure (24.3 vs. 16.3 years, p=0.097), consumed more pork (97.1% vs. 73.6%, p=0.001), and were more often a member of the Iraqw tribe (94.3% vs. 67.8%, p=0.005) than PWE without NCC (n=177). PWE and NCC who were compliant with anti-epileptic medications had a significantly higher reduction of seizures (98.6% vs. 89.2%, p=0.046). Other characteristics such as gender, seizure frequency, compliance, past medical history, close contact with pigs, use of latrines and family history of seizures did not differ significantly between the two groups. The number of NCC lesions and active NCC lesions were significantly associated with a positive antibody result. The electroimmunotransfer blot, developed by the Centers for Disease Control and Prevention, was more sensitive than a commercial western blot, especially in PWE and cerebral calcifications. This is the first study to systematically compare the clinical characteristics of PWE due to NCC or other causes and to explore the utility of two different antibody tests for diagnosis of NCC in sub-Saharan Africa.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21666796 PMCID: PMC3110162 DOI: 10.1371/journal.pntd.0001185
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Flow chart for the recruitment of patients.
For more details see Methods.
Demographic data, clinical characteristics and associated factors of people with epilepsy with and without neurocysticercosis.
| Characteristics | PWE with NCC | PWE without NCC | Total | ||
| Age at examination day in years | N | 35 | 177 | 212 | |
| p = 0.530 | Mean (SD) | 32.5 (20.6) | 27.3 (12.7) | 28.2 (14.4) | |
| Median (range) | 22 (13–83) | 24 (11–72) | 24 (11–83) | ||
| Age at first seizure in years | N | 35 | 176 | 211 | |
| p = 0.097 | Mean (SD) | 24.3 (22.0) | 16.3 (12.2) | 17.7 (14.5) | |
| Median (range) | 17 (0.1–77) | 14 (0.3–64) | 14 (0.1–77) | ||
| Gender | Male | N (%) | 21 (60.0) | 87 (49.2) | 108 (50.9) |
| p = 0.270 | Female | N (%) | 14 (40.0) | 90 (50.8) | 104 (49.1) |
| Tribe | Iraqw | N (%) | 33 (94.3) | 120 (67.8) | 153 (72.2) |
|
| Datoga | N (%) | 2 (5.7) | 27 (15.3) | 29 (13.7) |
| Bantu tribes | N (%) | 0 (0.0) | 28 (15.8) | 28 (13.2) | |
| Other | N (%) | 0 (0.0) | 2 (1.1) | 2 (0.9) | |
| Educational level | None | N (%) | 14 (40.0) | 53 (30.1) | 67 (31.8) |
| p = 0.734 | Less than 7 years | N (%) | 9 (25.7) | 49 (27.8) | 58 (27.5) |
| Primary school (7 years) | N (%) | 12 (34.3) | 68 (38.6) | 80 (37.9) | |
| 7–11 years | N (%) | 0 (0.0) | 1 (0.6) | 1 (0.5) | |
| Secondary school (11 years) | N (%) | 0 (0.0) | 5 (2.8) | 5 (2.4) | |
| Type of seizure | Gwa | N (%) | 15 (42.9) | 100 (56.5) | 115 (54.2) |
| p = 0.461 | Gfs | N (%) | 7 (20.0) | 33 (18.6) | 40 (18.9) |
| Goa | N (%) | 8 (22.9) | 22 (12.4) | 30 (14.2) | |
| Gbd | N (%) | 2 (5.7) | 11(6.2) | 13 (6.1) | |
| Tt | N (%) | 3 (8.6) | 9 (5.1) | 12 (5.7) | |
| U | N (%) | 0 (0.0) | 2 (1.1) | 2 (0.9) | |
| Frequency of seizures / month before Tx | N | 26 | 153 | 179 | |
| p = 0.461 | Mean (SD) | 6.8 (14.1) | 7.8 (19.3) | 7.7 (18.6) | |
| Median (range) | 2.75 (0.1–70) | 3 (0.1–180) | 3 (0.1–180) | ||
| Frequency of seizures / month after Tx in 2006 | N | 35 | 175 | 210 | |
| p = 0.093 | Mean (SD) | 0.4 (0.8) | 0.8 (2.6) | 0.8 (2.4) | |
| Median (range) | 0 (0–3) | 0.2 (0–29.5) | 0.2 (0–29.5) | ||
| Compliance with Tx | Compliant | N (%) | 14 (42.4) | 95 (53.7) | 109 (51.9) |
| p = 0.259 | Non-compliant | N (%) | 19 (57.6) | 82 (46.3) | 101 (48.1) |
| Reduction of seizure frequency in 2006 in percent | N | 32 | 169 | 201 | |
| All PWE | Mean (SD) | 90.2 (21.9) | 81.6 (29.5) | 82.9 (28.5) | |
| p = 0.081 | Median (range) | 100 (0–100) | 97.8 (0–100) | 99.6 (0–100) | |
| Reduction of seizure frequency in 2006 in percent | N | 16 | 80 | 96 | |
| Non compliant | Mean (SD) | 82.2 (29.0) | 73.0 (34.1) | 74.6 (33.3) | |
| p = 0.362 | Median (range) | 96.5 (0–100) | 87.0 (0–100) | 89.3 (0–100) | |
| Reduction of seizure frequency in 2006 in percent | N | 14 | 89 | 103 | |
| All Compliant: | Mean (SD) | 98.6 (3.6) | 89.2 (22.1) | 90.5 (20.8) | |
|
| Median (range) | 100 (89–100) | 100 (0–100) | 100 (0–100) | |
| Reduction of seizure frequency in 2006 in percent | N | 9 | 65 | 74 | |
| Compliant on Carbamazepine | Mean (SD) | 99.0 (2.8) | 89.2 (21.7) | 90.4 (20.6) | |
| p = 0.069 | Median (range) | 100 (92–100) | 98.8 (0–100) | 100 (0–100) | |
| Reduction of seizure frequency in 2006 in percent | N | 5 | 21 | 26 | |
| Compliant on Phenobarbitone | Mean (SD) | 97.8 (5.0) | 87.9 (24.7) | 89.8 (22.5) | |
| p = 0.294 | Median (range) | 100 (89–100) | 100 (0–100) | 100 (0–100) | |
| Family history of seizures | n = 212; p = 0.688 | N (%) | 11 (31.4) | 50 (28.2) | 61 (28.8) |
| PPH of depression | n = 211; p = 0.224 | N (%) | 0 (0.0) | 12 (6.8) | 12 (5.7) |
| PPH of psychotic episodes | n = 212; p = 1.000 | N (%) | 1 (2.9) | 5 (2.8) | 6 (2.8) |
| PPH of mental retardation | n = 212; p = 1.000 | N (%) | 4 (11.4) | 23 (13.0) | 27 (12.7) |
Gwa...Generalised seizures that started within a specific age range (seizures most likely due to idiopathic epilepsy), Gfs...Generalised seizures with obvious focal neurological signs, Goa...Generalised seizures that started outside the age range of idiopathic epilepsies but without any obvious sign or history of an underlying cause, Gbd...Generalised seizures with more widespread brain damage, Tt...Two different seizure types, U...Unclassified epileptic seizures; for more details see Winkler et al. [19] PWE... People with epilepsy, NCC... Neurocysticercosis, Tx... Anti-epileptic treatment, PPH... Past psychiatric history.
Frequency of potential risk factors of neurocysticercosis in people with epilepsy with and without neurocysticercosis.
| Potential risk factors of NCC | PWE with NCC | PWE without NCC | Total | ||
| Number of people in household | N | 35 | 174 | 209 | |
| p = 0.856 | Mean (SD) | 6.9 (3.0) | 7.4 (4.2) | 7.3 (4.0) | |
| Median (range) | 6 (2–13) | 7 (1–30) | 7 (1–30) | ||
| Number of pigs in household | N | 35 | 174 | 209 | |
| p = 0.370 | Mean (SD) | 1.3 (2.0) | 1.1 (2.0) | 1.1 (2.0) | |
| Median (range) | 0 (0–10) | 0 (0–10) | 0 (0–10) | ||
| Close contact with pigs | n = 212; p = 0.351 | N (%) | 17 (48.6) | 70 (39.5) | 87 (41.0) |
| Pork consumption | n = 209; | N (%) | 34 (97.1) | 128 (73.6) | 162 (77.5) |
| Use of latrine | n = 209; p = 1.000 | N (%) | 34 (97.1) | 169 (97.1) | 203 (97.1) |
PWE... People with epilepsy, NCC... Neurocysticercosis.
Diagnosis of neurocysticercosis according to Del Brutto et al. using two different antibody tests.
| Diagnosis of NCC | Commercial Western blot | CDC EITB | ||||||
| n | Positive | Negative | nt | n | Positive | Negative | nt | |
| No NCC | 183 (86.3%) | 0 | 20 | 163 | 177 (83.5%) | 0 | 47 | 130 |
| Probable NCC | 22 (10.4%) | 0 | 13 | 9 | 18 (8.5%) | 6 | 11 | 1 |
| Definitive NCC | 7 (3.3%) | 6 | 1 | 0 | 17 (8.0%) | 17 | 0 | 0 |
*According to NCC diagnostic criteria of Del Brutto et al. [21], [22]
NCC... Neurocysticercosis, CDC EITB... Electroimmunotransfer blot developed by the Centers for Disease Control and Prevention, Atlanta, GA, USA, nt... Not tested.
Number and activity of neurocysticercosis lesions on cerebral computed tomography scan and cysticercosis antibody results.
| Number of NCC | EITB CDC | Commercial Western Blot | CSF both tests | |||
| lesions on CT scan | Negative | Positive | Negative | Positive | Negative | Positive |
| 0 | 42 (91.3%) | 4 (8.7%) | 20 (100%) | 0 (0.0%) | 0 | 0 |
| 1 | 7 (77.8%) | 2 (22.2%) | 0 | 0 | 0 | 0 |
| 2–4 | 5 (45.5%) | 6 (54.5%) | 6 (100%) | 0 (0.0%) | 3 (100%) | 0 (0.0%) |
| ≥5 | 4 (26.7%) | 11 (73.3%) | 8 (57.1%) | 6 (42.9%) | 3 (37.5%) | 5 (62.5%) |
| Total | 58 (71.6%) | 23 (28.4%) | 34 (85.0%) | 6 (15.0%) | 6 (54.5%) | 5 (45.5%) |
|
| ||||||
| Inactive | 16 (55.2%) | 13 (44.8%) | 13 (92.9%) | 1 (7.1%) | 6 (85.7%) | 1 (14.3%) |
| Active | 0 (0%) | 6 (100%) | 1 (16.7%) | 5 (83.3%) | 0 (0%) | 4 (100%) |
*Including active and inactive lesions; NCC... Neurocysticercosis, CDC EITB... Electroimmunotransfer blot developed by the Centers for Disease Control and Prevention, in Atlanta, GA, USA, CSF... Cerebrospinal fluid, CT...Computed tomography.